CLINICAL_TRIALS
trial_result
· 2025-01-17
Clinical Trial Update: ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection [Phase 2]
Summary
Phase 2 trial results for ACX-362E (Ibezapolstat) in treating Clostridioides difficile infection have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Acurx Pharmaceuticals Inc. | Conditions: Clostridium Difficile Infection | Phase 2 | Status: COMPLETED | Results posted: 2025-01-17